



KAREN L. SMITH, MD, MPH  
Director & State Health Officer

State of California—Health and Human Services Agency  
California Department of Public Health



EDMUND G. BROWN JR.  
Governor

OFFICE OF AIDS (OA)  
AIDS Drug Assistance Program (ADAP)

Management Memorandum  
Memorandum Number: 2016-04

Date: March 30, 2016

TO: LOCAL ADAP COORDINATORS  
ADAP ENROLLMENT WORKERS

SUBJECT: ADDITION OF EMTRICITABINE/RILPIVIRINE/TENOFOVIR  
ALAFENAMIDE (ODEFSEY®) TO THE ADAP FORMULARY

**Effective March 30, 2016**, emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg (R/F/TAF) (Odefsey®) has been added to the ADAP formulary. This three drug combination antiretroviral (ARV) medication was approved by the federal Food and Drug Administration (FDA) on March 1, 2016. This ARV is a once-daily tablet which is to be taken with food for treatment of patients with no treatment history or as a replacement therapy for patients who are virally suppressed.

With the addition of this ARV, the ADAP formulary consists of 197 drugs, including those necessary to treat HIV in accordance with the federal treatment guidelines for HIV/AIDS and associated opportunistic infections.

If you have any questions regarding the addition of this drug to the ADAP formulary, please contact me at (916) 449-5942 or Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.

Niki Dhillon, Chief  
ADAP Branch  
Office of AIDS